D. E. Shaw & Co., Inc. Agios Pharmaceuticals, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 596,202 shares of AGIO stock, worth $25.4 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
596,202
Previous 554,820
7.46%
Holding current value
$25.4 Million
Previous $16.3 Million
21.98%
% of portfolio
0.02%
Previous 0.02%
Shares
31 transactions
Others Institutions Holding AGIO
# of Institutions
240Shares Held
62MCall Options Held
297KPut Options Held
235K-
Farallon Capital Management LLC San Francisco, CA5.77MShares$246 Million0.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.68MShares$242 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$207 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.59MShares$153 Million2.72% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.33MShares$99.2 Million0.65% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $2.34B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...